For the quarter ended December 2023, Gilead Sciences (GILD) reported revenue of $7.12 billion, down 3.7% over the same period last year. EPS came in at $1.72, compared to $1.67 in the year-ago quarter. The reported revenue represents a surprise of +0.51% over the Zacks Consensus Estimate of $7.08 billion. With the consensus EPS estimate being $1.76, the EPS surprise was -2.27%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

业绩总结 - 公司2023财年总产品销售额同比增长7%，达到247亿美元[10][125] - 公司2023财年HIV产品销售额同比增长6%，约50%的销售增长由需求推动[10][29] - 公司2023财年肿瘤药品销售额同比增长37%，达到29亿美元[10][127] - 公司2023财年非GAAP数据显示成本和费用增长幅度适度，运营利润下降14%[129] - 公司2024财年产品销售（不包括Veklury）预计同比增长4-6%[146] 产品销售 - 公司Q423总产品销售额同比持平，环比持平[10][22] - 公司Q423总产品销售额同比下降4%，环比增长1%[22] - 公司Q423肿瘤药品销售额同比增长24%[22] - 公司Q423销售额为720百万美元，同比下降28%，环比增长13%[67] - 公司Q423销售额为299百万美元，同比增长53%，环比增长5%[75] 新产品和技术研发 - 公司Veklury对抗COVID-19持续领先[59] - 公司肿瘤学细胞疗法管线包括多个临床阶段项目，涉及多种癌症类型[187] - 公司2023年第四季度新增了一些突破性治疗项目[193] 市场扩张和并购 - 公司在2023年第四季度结束时，与Merck、Arcus Biosciences等公司合作进行了多个肿瘤项目[192] 未来展望 - 公司2024财年R&D支出预计低至中单位数增长，SG&A支出预计中单位数下降[145] - 公司2024财年产品销售（不包括Veklury）预计同比增长4-6%，HIV销售预计同比增长约4%[146]

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Scien ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, including updates ...

Gilead Sciences Inc. (GILD) is set to report fourth-quarter 2023 results on Feb 6, after market close. The company has a mixed track record, with earnings beating estimates in two of the last four quarters and missing in the remaining two, the average negative surprise being 0.24%. In the last reported quarter, the company posted an earnings surprise of 19.9%. Factors to Note Revenues in the fourth quarter have likely been boosted by growth in oncology and HIV franchise sales. However, a decline in Veklury ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global co ...

Analysts on Wall Street project that Gilead Sciences (GILD) will announce quarterly earnings of $1.76 per share in its forthcoming report, representing an increase of 5.4% year over year. Revenues are projected to reach $7.08 billion, declining 4.2% from the same quarter last year. The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial esti ...

Gilead Sciences (GILD) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on February 6, 2024, might help the stock move higher if these key numbers are better ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup New ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manufactur ...